IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia
Status:
RECRUITING
Trial end date:
2028-11-30
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm clinical study designed to evaluate the efficacy and safety of IL-5 CAR-T cell therapy in the treatment of patients with CD125-positive eosinophilic leukemia.